Company news
Galmed Pharmaceuticals Ltd. news in 2025
Galmed Pharmaceuticals Ltd.'s news releases, calls and decks from 2025, newest first.
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
December 8, 2025
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
December 4, 2025
Galmed Issues CEO Letter to Shareholders
December 1, 2025
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 26, 2025
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
November 18, 2025
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
November 17, 2025
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 28, 2025
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
August 25, 2025
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
May 27, 2025
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 22, 2025
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
May 13, 2025
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
May 6, 2025
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
April 28, 2025
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
April 17, 2025
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
April 15, 2025
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
April 10, 2025
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
April 2, 2025
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
March 20, 2025